USPTO serial 79144403
NEOFORDEX
Reviewed by CopyMark Law Group
Reg. 4705767Status 404
- Filing date
- Status date
- Registration date
- Mar 24, 2015
- Examiner
- GRIFFIN, JAMES
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEOFORDEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
M. Scott Alprin
M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, DC 20015UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; chemical preparations for medical and pharmaceutical use for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 17, 2024 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 17, 2024 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 12, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Oct 2, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 7, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 7, 2022 | INPC | INVALIDATION PROCESSED | — |
| Jul 26, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 26, 2021 | C71T | CANCELLED SECTION 71 | — |
| May 7, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 24, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 15, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 18, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 30, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 30, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 24, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 6, 2015 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 24, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 6, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 6, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 3, 2015 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 17, 2014 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 17, 2014 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 17, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 1, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 22, 2014 | ALIE | ASSIGNED TO LIE | — |
| Nov 4, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 4, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 4, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 4, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 4, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 1, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 31, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 31, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 23, 2014 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 2, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 2, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 2, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 1, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 1, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 28, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 27, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |